|
HEALTHCARE PROFESSIONALS
The information in this section is solely intended for
healthcare professionals and biomedical investigators.
ActivaMune is available on a wholesale basis to
certified healthcare professionals. Interested professionals
should scan their credentials / business license into a PDF file and
e-mail it to us for consideration. Upon approval, you will receive wholesale
account information from our customer service department. Please send your
information to the following e-mail address for consideration:
Important note for readers:
while many of the scientific discoveries and clinical developments listed in
this section are extremely exciting, they are stepping stones in the studies
of Diindolylmethane (DIM) and some of the other key natural ingredients in
ActivaMune. The exploration of clinical applications for Diindolylmethane is
an emerging science. Only the US FDA has the authority to recognize a compound as a
drug or therapeutic for a particular condition in the US and that only
occurs after the compound has been thoroughly studied and its efficacy
established in four consecutive human clinical trials. At this point in
time, Diindolylmethane and the other natural ingredients in ActivaMune are
regarded as dietary supplements and not therapeutics for any specific
condition by the US FDA. ActivaMune is a nutritional supplement. The
statements on this website have not been evaluated by the US Food and Drug
Administration. ActivaMune is not intended to diagnose, treat, cure or
prevent any disease.
SCIENTIFIC BRIEFING FOR
HEALTHCARE PROFESSIONALS AND BIOMEDICAL INVESTIGATORS
Diindolylmethane (DIM)
Immune Modulating Properties
Induction of Interferon-Gamma Receptors on Cell
Surfaces
Stimulation of Interferon-Gamma,
G-CSF, IL-12 & IL-6 Production
Synergy with Interferon-Gamma
in Expression of the MHC-I Complex
Selection of Data from the Reference Section
DIM In-Vivo Affect on Key Immune
Modulating Cytokines
In this study DIM was
administered orally at 30mg/kg of body weight.
DIM In-Vivo Anti-Viral Activity
Through Immune Modulation
(Reference: Xue L, Pestka J, Maoxiang L,
Firestone GL, Bjeldanes LF, 3,3′-Diindolylmethane stimulates murine
immune function in vitro and in vivo, Journal of Nutritional
Biochemistry,
published online, 8-20-07.)
DIM Stimulates Transcript Expression of Interferon-γ
and Related Genes in Human Breast Cancer Cells
Activation and Potentiation of Interferon-γ by DIM:
Stimulation of Interferon-γ Receptor 1 Production
Potentiation of Interferon-γ Mediated Cell Cycle Arrest by DIM in Human Breast Cancer Cells
DIM Enhances Interferon-γ Induced Expression of MHC-I Complex in Human Breast Cancer Cells
(Please Note Section D of this figure.
DIM may be used as an adjuvant
to IFNγ treatment models because of this unique synergistic effect on the MHC-I Complex.
This synergy is currently under investigation for HIV, HPV, Hepatitis
and multiple forms of cancer.)
Fig 8. The expression level of MHC-I complex on the MCF-7 cell
surface. A, cells were treated with different concentrations of IFN-Gamma for 16 h. B and C, cells
were pretreated with DMSO (control) or 30
΅M DIM for 48 h, followed by 0.1 ng/ml of
IFN-Gamma (B) or 10 ng/ml of IFN-Gamma (C) for another 16 h. One
million cells were incubated in 90
΅l of
PBS with 10
΅l of
FITC-conjugated anti-HLA-ABC mouse monoclonal antibody. The fluorescence
intensity was measured by flow cytometry using a Coulter Elite instrument and
analyzed by WinMDI 2.8 software provided by Duke University. D, the expression
of HLA class I complex was calculated as %PC (open bars) and MFV (cross-hatched
bars).
(Reference: Riby
JE, Xue L, Chatterji U, Bjeldanes EL, Firestone GL, Bjeldanes LF,
Activation and Potentiation of Interferon-(gamma) Signaling by
3,3'-Diindolylmethane in MCF-7 Breast Cancer Cells, Molecular
Pharmacology, Nov. 2, 2005)
DIM and Taxol Synergize to Promote Apoptosis
(Reference: K. McGuire, N. Ngoubilly, M. Neavyn,
S. Lanza-Jacoby. 3,3′-Diindolylmethane and Paclitaxel Act Synergistically
to Promote Apoptosis in HER2/Neu Human Breast Cancer Cells. Journal of
Surgical Research, 2006 May 15;132(2):208-13. Department of Surgery,
Jefferson Medical College, Thomas Jefferson University, Philadelphia,
Pennsylvania 19107)
In-Vivo Animal Study: DIM Inhibits DMBA-induced
Mammary Tumor Growth
(Reference: Chen I, McDougal A, Wang F, Safe S,
Carcinogenesis, vol. 19, no.9. pp.1631. 1998.)
In-Vivo Animal Study: DIM Inhibits Growth
of Human Mammary Tumor Cells in Athymic Mice
(Reference: Chang
X., Tou J.C., Hong C., Kim H.A., Riby J.E., Firestone G.L., Bjeldanes L.F.,
3,3'-Diindolylmethane inhibits angiogenesis and the growth of
transplantable human breast carcinoma in athymic mice, Carcinogenesis,
Janurary 2005, pp.771-778.)
Additional References
on Diindolylmethane (DIM)
General information about
DIM is available at the
Diindolylmethane Information Resource Center
Detailed information regarding DIM's immune
activation properties is available at the
Diindolylmethane Immune Activation Data Center
|
